Literature DB >> 9288015

Baseline correlates with quality of life among men and women with medication-controlled hypertension. The trial of nonpharmacologic interventions in the elderly (TONE).

R T Anderson1, P Hogan, L Appel, R Rosen, S A Shumaker.   

Abstract

OBJECTIVES: To examine Quality of Life (QOL) and its correlates among older adults with medication-controlled hypertension.
DESIGN: Baseline data from the TONE clinical trial. MEASUREMENTS: Demographic variables (age, race, income), hypertension treatment (medication class, years treated), health status (obesity, physical symptoms), and QOL status (MOS-Short-Form 36, Jenkins Sleep Disturbance, and CES-D Depression). PARTICIPANTS: A total of 975 men and women, aged 60 to 81 years and free of major diseases and disability, with a screening blood pressure (BP) of < or = 145/85 mm Hg, treated medically for hypertension with antihypertensive medication.
RESULTS: On average, TONE participants reported a QOL level on the SF-36 that was similar to or better than that reported by older adults in the general population. However, there was a strikingly high prevalence of physical complaints or symptoms: 90.3% of men and 93.3% of women experienced one or more physical symptoms or complaints, and nearly 50% reported that such symptoms had disrupted their daily functioning. Among variables-considered, only the physical symptoms index score, number of severe symptoms, and obesity status were correlated consistently with QOL among TONE men and women. Lower QOL scores were associated with higher symptom scores and with obesity. Neither medication class nor age were appreciably associated with QOL status.
CONCLUSIONS: Physical symptoms, rather than medication class and age, were the strongest correlates of QOL in TONE. This underscores the importance of identifying the etiology of symptoms as a means to improve the QOL of order hypertensive persons rather than substituting medication. The association of poorer physical well-being with obesity suggests that weight reduction to manage BP may also improve QOL for some individuals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288015     DOI: 10.1111/j.1532-5415.1997.tb05970.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  8 in total

Review 1.  Quality of life with nonpharmacologic treatment of hypertension.

Authors:  J P Roel; C L Hildebrant; R H Grimm
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  A systematic review of patient-reported outcome instruments measuring sleep dysfunction in adults.

Authors:  Emily Beth Devine; Zafar Hakim; Jesse Green
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Influence of chronic cardiovascular disease and hospitalisation due to this disease on quality of life of community-dwelling elderly.

Authors:  Ewa Borowiak; Tomasz Kostka
Journal:  Qual Life Res       Date:  2006-09-14       Impact factor: 4.147

4.  Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis.

Authors:  R P Mills
Journal:  Trans Am Ophthalmol Soc       Date:  1998

5.  Effect of elevated blood pressure on quality of life in children with chronic kidney disease.

Authors:  Cynthia Wong; Arlene Gerson; Stephen R Hooper; Matthew Matheson; Marc Lande; Juan Kupferman; Susan Furth; Bradley Warady; Joseph Flynn
Journal:  Pediatr Nephrol       Date:  2016-02-08       Impact factor: 3.714

6.  Childhood hypertension is not a silent disease.

Authors:  Beth Croix; Daniel I Feig
Journal:  Pediatr Nephrol       Date:  2006-02-21       Impact factor: 3.714

7.  Reduction in adverse symptoms as blood pressure becomes controlled.

Authors:  Cynthia A Weber; Megan R Leloux; Barry L Carter; Karen B Farris; Yinghui Xu
Journal:  Pharmacotherapy       Date:  2008-09       Impact factor: 4.705

8.  Quality of life in a sample of hypertensive patients attending primary health care facilities in Al-khobar, saudi arabia.

Authors:  Mohammed S Al-Ghamdi; Attia Z Taha; Bahnassy Ahmad; Mohammed S Khalil
Journal:  J Family Community Med       Date:  2002-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.